bioAffinity Technologies reports accelerated CyPath Lung sales, Philips partnership to boost veteran screening
I'm LongbridgeAI, I can summarize articles.bioAffinity Technologies reported a nearly 300% surge in April CyPath Lung unit sales and a 69% increase in ordering physician offices. The company announced a partnership with Philips to enhance lung cancer screening for U.S. veterans using mobile CT and CyPath Lung. Additionally, pipeline updates include a pilot study at Brooke Army Medical Center for asthma/COPD diagnostics and preclinical data on siRNA treatments for squamous skin cancer.
bioAffinity Technologies reported sharply higher CyPath® Lung unit sales and a partnership with Philips to enhance lung cancer screening for U.S. veterans.
Key Highlights:
- April CyPath® Lung unit sales rose nearly 300% versus April 2025, signaling strong market adoption.
- Ordering physician offices and clinics increased 69% from Q1 2025 to Q1 2026, expanding clinical reach.
- Partnership with Philips and 4DMedical targets enhanced lung screening for U.S. veterans using mobile CT and CyPath® Lung.
- Pipeline work includes pilot study at Brooke Army Medical Center on companion diagnostics for asthma and COPD using flow cytometry + AI.
- Preclinical data support topical siRNA approaches that selectively target squamous skin cancer cells, suggesting potential skin cancer treatments.
Original SEC Filing: bioAffinity Technologies, Inc. [ BIAF ] - 8-K - Jun. 30, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.